RUA Life Sciences (GB:RUA)
LSE:RUA
Want to see GB:RUA full AI Analyst Report?
RUA Stock Chart & Stats
14.00 p
-0.50 p(-3.85%)
At close: 4:00 PM EST
14.00 p
-0.50 p(-3.85%)
Day’s Range― - ―
52-Week Range10.42 p - 20.94 p
Previous CloseN/A
Volume378.53K
Average Volume (3M)148.53K
Market Cap
£12.10M
Enterprise Value10.21M
Total Cash (Recent Filing)£3.25M
Total Debt (Recent Filing)£794.00K
Price to Earnings (P/E)3.6
Beta0.42
Next Earnings
Jul 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding62,060,272
10 Day Avg. Volume90,619
30 Day Avg. Volume148,527
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)£7.16M
Bulls Say, Bears Say
Bulls Say
Revenue Scale & High Gross MarginMeaningful multi-year revenue growth combined with a ~69% gross margin shows durable unit economics and improving market adoption of products. Strong gross margins provide ongoing capacity to fund R&D, commercialisation and manufacturing scale without immediate margin pressure, supporting longer-term margin sustainability if revenue growth continues.
Conservative Capital StructureVery low leverage provides financial flexibility and reduces insolvency risk, enabling the company to invest in product development or absorb cyclical shocks. A conservative balance sheet also improves ability to access external capital on reasonable terms, supporting execution of growth plans over the medium term without forcing distressed financing.
Specialised Medtech CapabilitiesSpecialist expertise in polymer biomaterials and contract manufacturing creates higher barriers to entry and stickier customer relationships. Supplying regulated, technical components to medtech customers supports recurring revenue potential and long-term client partnerships, underpinning a durable business model and defensible market position in niche medical device supply chains.
Bears Say
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow means the business is not yet self-funding and will remain reliant on external capital if losses continue. Over months this elevates refinancing and dilution risk, constrains discretionary investment, and can limit ability to scale manufacturing or absorb shocks without raising additional funds.
Operating Profitability Not EstablishedDespite improving trends, continued negative EBIT margin indicates core operations have yet to reach sustainable profitability. If underlying cost structure or SG&A scale-up persists, converting revenue growth into operating profit may take additional time, exposing margins to pressure and delaying internal cash generation needed for long-term stability.
Negative Return On EquityA negative ROE shows the company has not yet delivered positive returns on invested capital, reducing internal incentive signals and investor confidence. Persistently low or negative ROE can limit ability to finance growth from retained earnings and may increase reliance on external financing, which can dilute existing shareholders or raise cost of capital over time.
RUA Life Sciences News
RUA FAQ
What was RUA Life Sciences’s price range in the past 12 months?
RUA Life Sciences lowest share price was 10.42 p and its highest was 20.94 p in the past 12 months.
What is RUA Life Sciences’s market cap?
RUA Life Sciences’s market cap is £12.10M.
When is RUA Life Sciences’s upcoming earnings report date?
RUA Life Sciences’s upcoming earnings report date is Jul 13, 2026 which is in 69 days.
How were RUA Life Sciences’s earnings last quarter?
RUA Life Sciences released its earnings results on Jan 30, 2026. The company reported 0.008 p earnings per share for the quarter, beating the consensus estimate of N/A by 0.008 p.
Is RUA Life Sciences overvalued?
According to Wall Street analysts RUA Life Sciences’s price is currently Overvalued.
Does RUA Life Sciences pay dividends?
RUA Life Sciences does not currently pay dividends.
What is RUA Life Sciences’s EPS estimate?
RUA Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RUA Life Sciences have?
RUA Life Sciences has 62,060,272 shares outstanding.
What happened to RUA Life Sciences’s price movement after its last earnings report?
RUA Life Sciences reported an EPS of 0.008 p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -7.937%.
Which hedge fund is a major shareholder of RUA Life Sciences?
Currently, no hedge funds are holding shares in GB:RUA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RUA Life Sciences
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
Technical Analysis
Creo Medical
―
Genedrive
―
Inspiration Healthcare
―
OptiBiotix Health
―
Surgical Innovations
―
Options Prices
Currently, No data available
---